MP49-16 COMPARISON OF ROBOT-ASSISTED PARTIAL NEPHRECTOMY AND PERCUTANEOUS ABLATION FOR CT1 RENAL MASSES: MID TERM OUTCOME ANALYSIS

Abstract

You have accessJournal of UrologyKidney Cancer: Localized: Surgical Therapy IV (MP49)1 Sep 2021MP49-16 COMPARISON OF ROBOT-ASSISTED PARTIAL NEPHRECTOMY AND PERCUTANEOUS ABLATION FOR CT1 RENAL MASSES: MID TERM OUTCOME ANALYSIS Umberto Carbonara, Alp Tuna Beksac, Alessandro Larcher, Fabio Crocerossa, Lance Hampton, Ithaar Derweesh, Umberto Capitanio, Francesco Montorsi, Jihad Kaouk, and Riccardo Autorino Umberto CarbonaraUmberto Carbonara More articles by this author , Alp Tuna BeksacAlp Tuna Beksac More articles by this author , Alessandro LarcherAlessandro Larcher More articles by this author , Fabio CrocerossaFabio Crocerossa More articles by this author , Lance HamptonLance Hampton More articles by this author , Ithaar DerweeshIthaar Derweesh More articles by this author , Umberto CapitanioUmberto Capitanio More articles by this author , Francesco MontorsiFrancesco Montorsi More articles by this author , Jihad KaoukJihad Kaouk More articles by this author , and Riccardo AutorinoRiccardo Autorino More articles by this author View All Author Informationhttps://doi.org/10.1097/JU.0000000000002075.16AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: Partial nephrectomy (PN) is one of the established treatment for cT1 renal masses. With the rapid dissemination of robotic surgery in the past ten years, RAPN has become “de facto” the new gold-standard for nephron-sparing surgery. In this scenario, percutaneous thermal ablation (PTA) represents a valid alternative to the nephron-sparing option. We aim to compare oncological outcomes of patients with cT1 renal mass undergoing RAPN vs. PTA. METHODS: Overall, a total of 1767 patients with primary cT1N0M0 renal masses treated between 2006 and 2019 were identified from a multicenter dataset. Data collected included baseline, pathological, perioperative, and postoperative features. The RAPN data were compared with those of PTA. Local recurrence-free, metastases-free, and overall survival rates were estimated using the Kaplan-Meier method and compared with log-rank tests. RESULTS: Of the 1767 patients, 1039 and 728 underwent RRAPN and PTA, respectively. In our cohort, patients who underwent RAPN reported a lower median age (58 vs. 64 years, p=0.005) as well as lower Charlson comorbidity scores. The mean tumor size was 3 and 4cm in PTA and RAPN, respectively. Median follow up was similar among the groups (45 vs. 48months, p=0.1). Local recurrence-free survival was similar among the treatments (p=0.38). Metastases-free survival was significantly better after RAPN (p=0.001). Overall survival was high for RAPN patients (p<0.001). CONCLUSIONS: In a large cohort of cT1 renal masses, we observed that recurrence-free survival was similar for RAPN and percutaneous ablation patients. Metastases-free survival was superior for RAPN patients, as well as overall survival. Source of Funding: None © 2021 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 206Issue Supplement 3September 2021Page: e882-e882 Advertisement Copyright & Permissions© 2021 by American Urological Association Education and Research, Inc.MetricsAuthor Information Umberto Carbonara More articles by this author Alp Tuna Beksac More articles by this author Alessandro Larcher More articles by this author Fabio Crocerossa More articles by this author Lance Hampton More articles by this author Ithaar Derweesh More articles by this author Umberto Capitanio More articles by this author Francesco Montorsi More articles by this author Jihad Kaouk More articles by this author Riccardo Autorino More articles by this author Expand All Advertisement Loading ...